诱导化疗后中期FDG PET-CT预测头颈癌同步放化疗疗效与预后
回顾性分析43例接受TPF方案诱导化疗后同步放化疗的头颈癌患者,于诱导化疗前后行FDG PET-CT,评估代谢反应与放化疗完全缓解及生存的关系。淋巴结SUVmax和总MTV下降幅度在完全缓解组更大,总MTV下降≥78%和淋巴结SUVmax下降≥73%可预测完全缓解及更长OS和PFS。
要点
- 诱导化疗后淋巴结SUVmax和总MTV下降幅度在放化疗完全缓解组大于非完全缓解组。
- 总MTV下降≥78%和淋巴结SUVmax下降≥73%可预测同步放化疗完全缓解。
- 上述代谢指标下降幅度较大者总生存和无进展生存更长。
核心结论
- 诱导化疗三周期后中期FDG PET-CT测量SUVmax和总MTV可能有助于识别将从同步放化疗获益的头颈癌患者并预测生存结局。
研究设计与样本
- 回顾性研究,纳入43例头颈癌患者,中位随访32.7个月。
- 患者接受多西他赛、顺铂和5-氟尿嘧啶(TPF)诱导化疗三周期后行同步放化疗。
- 于诱导化疗前后行FDG PET-CT,依据实体瘤疗效评价标准评估同步放化疗后肿瘤反应。
主要发现
- 同步放化疗完全缓解组淋巴结SUVmax下降88.8% vs 非完全缓解组62.5%。
- 同步放化疗完全缓解组总MTV下降99.7% vs 非完全缓解组89.9%。
- 诱导化疗后总MTV下降≥78%和淋巴结SUVmax下降≥73%可预测同步放化疗完全缓解及更长总生存和无进展生存。
关键数值与推荐
- 总MTV下降≥78%和淋巴结SUVmax下降≥73%为预测同步放化疗完全缓解及更长OS和PFS的阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性研究。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Induction chemotherapy (ICT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiotherapy (CCRT) has the advantages of organ preservation and systemic control in head and neck cancer (HNC). Early prediction of CCRT efficacy may help identify patients who will benefit more from surgery than from CCRT. We investigated the role of interim 18-fluoro-2-deoxy-glucose positron emission tomography computed tomography (FDG PET-CT) after ICT to predict the efficacy of CCRT and clinical outcomes. METHODS: Tumor responses were retrospectively reviewed after CCRT based on the Response Evaluation Criteria in Solid Tumors. FDG PET-CT imaging was performed before and after three cycles of TPF. We examined the associations between the metabolic response (percentage decrease in the maximum standardized uptake value [SUVmax] and total metabolic tumor volume [MTV]) after ICT and complete response (CR) to CCRT, progression-free survival (PFS), and overall survival (OS). RESULTS: We studied 43 HNC patients with a median follow-up of 32.7 months. Lymph node (LN) SUVmax and total MTV decreases from baseline after ICT were greater in patients with a CR to CCRT than in non-CR patients (LN SUVmax, 88.8% vs. 62.5%, respectively; total MTV, 99.7% vs. 89.9%, respectively). Decreases in total MTV ≥ 78% and LN SUVmax ≥73% after ICT predicted CR to CCRT and longer OS and PFS. CONCLUSIONS: Using interim FDG PET-CT to measure SUVmax and total MTV after three cycles of ICT may be a useful technique for identifying HNC patients who will benefit from CCRT and predicting survival outcomes.
引用
- Kim KR, Shim HJ, Hwang JE, et al. The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 28940101. doi:10.1007/s00259-017-3836-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。